Feeds:
Posts
Comments

Posts Tagged ‘Bayer’

*****

TODAY’S NEWS:

Prostate cancer drug treatment (Sanofi) approved on the fast track. But – a warning flag for S-A about possible Lantus/cancer link.

Bayer and OncoMed to co-develop oncology drugs in new agreement.

Novartis‘ blood cancer drug Tasigna gets approval for earlier use with CML.

RECOMMENDED

SocialRx – pharma social media resources. A page full of goodies, newly updated from us here at Impactiviti. Enjoy!

PLUS

Sex pills for women. Count me among the skeptics. And, medical flops of the decade (from Forbes).

JUST FOR FUN

Just where in the world is that South Africa place??

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****
TODAY’S NEWS

Valeant goes for the niches. Deliberately.

Eli Lilly still chopping positions – Eli Lilly and Co. plans to cut 200 sales and marketing support jobs Friday in its U.S. biomedicine group, with more than half of those cuts taking place in Indianapolis, a company spokesman confirmed Thursday. The cuts are the latest wave of the drugmaker’s previously announced plans to chop 5,500 jobs worldwide by the end of 2011 in response to financial pressuresmore

InVentiv to be acquired by private equity firm.

Bayer gets new type of contraceptive approved – The Food and Drug Administration approved Natazia, which is the first in the U.S. to deliver doses of its two female hormones at four times during the drug’s 28-day treatment cycle, the agency said today in a statementmore. But then, what about that mystery recall of Yaz last year – who knew??

I don’t know, Mr Harper (Forbes) – isn’t it more accurate to say that an application has been rejected, rather than that a drug has been rejected, when a Complete Response Letter is issued? The semantics are important.

RECOMMENDED

Down – like, seriously depressed? Get Some Help.

PLUS

More doctors giving drug reps the cold shoulder. And, sunlit leaves in dark shadow (pic).

JUST FOR FUN

Astonishing stuff – A Showcase of 3-D Street Art Paintings. How do people do this?

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

TODAY’S NEWS

FDA warning letters to Lilly, Bayer, Amylin, Cephalon.

Wow: ARBs for hypertension reducing Alzheimer’s symptoms? – Drugs commonly used to lower blood pressure, sold by AstraZeneca Plc, Sanofi-Aventis SA and Merck & Co., may also reduce the risk of developing Alzheimer’s disease. Researchers from Boston University analyzed the medical records of more than 800,000 U.S. veterans and found those taking angiotensin receptor blockers were up to 24 percent less likely to develop dementia than patients on other medications. Patients already diagnosed with Alzheimer’s disease were half as likely to be admitted to a nursing home and had a 17 percent reduced risk of dying if they were taking the medicationsmore

FTC wants to put a stop to the “pay-to-delay” deals – Jon Leibowitz will hold a press conference today to ask Congress to include a provision in the health care reform bill to end deals in which brand-name drugmakers offer payments or other inducments to generic rivals to delay copycat versions of best-selling medsmore

RECOMMENDED

Product/Therapeutic training development (pharma/biotech/devices). Live training, modules, eLearning – we’ve got the expertise and customer-centric approach in our vendor/partner network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Social Media, Opportunity, and Serendipity – my guest post on the Hive Awards blog.

JUST FOR FUN

Visual awesomeness. Photo of Martian dune field. Quite spectacular!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Sanofi-Aventis suspends sale of Acomplia in Europe. Acomplia, an obesity drug that once looked like it would be a blockbuster for Sanofi-Aventis, is being pulled off the market in Europe. The EMEA, the European version of the FDA, said today that a key committee “concluded that the benefits of Acomplia no longer outweigh its risks and the marketing authorisation should be suspended across the European Union.”…more

Jim Edwards summarizes what he calls Pfizer‘s Race to the Bottom. With some similar commentary on Novartis‘ growth/shrinkage.

Merck announces more big cuts – As part of its earnings announcement, the drugmaker says it expects to eliminate approximately 7,200 positions – 6,800 active employees and 400 vacancies – across all areas of the company worldwide by the end of 2011, with about 40 percent of the total reductions coming in the US (see statement). This amounts to 12 percent of the workforce…more

Pfizer’s Chantix: going down…or up, depending on which continent you’re on…US researchers say even more warnings needed.

FDA: Another day, another stall – U.S. regulators have extended by three months their review of a proposed osteoporosis drug from Pfizer Inc to study the pill in more depth, a company spokeswoman said on Tuesday…more And, while we’re at it, a thumbs down (for now) for Abbott‘s new version of Vicodin. Oh, and hey, let’s delay Abbott’s new cholesterol drug while we’re in foot-dragging mode!

Novartis buys up Nektar’s pulmonary business – Nektar Therapeutics  today announced that Novartis AG has agreed to acquire from Nektar specific pulmonary delivery assets, technology, and intellectual property for $115 million in cash…more

Will BMS lead the charge in buying up undervalued biotechs?

Earnings roundup for Schering, Pfizer, Roche here’s the scoop.

What about Amgen’s growth? An interesting analysis here. Plus – how 6 pharma companies have dodged (or not) the current financial crisis (extracts from earnings announcements from Pfizer, Bayer, Abbott Labs, Gilead, Wyeth and Genentech, all on the topic of how each company has fared in the crisis.)

Celgene seems to be doing quite OK.

J&J’s HIV drug gets expanded approval – U.S. health regulators have expanded approval for Johnson & Johnson’s Prezista in combination with other drugs to treat HIV patients who are just beginning to take medication for the virus, the company said on Wednesday…more

Avastin: what doesn’t this drug do? – After tagging the antibody drug with a radioactive tracer and injecting it into mice, researchers found it successfully targeted cancer cells and this enabled them to produce well-defined images of tumours during scanning…more

Speaking of which, does leukemia drug Campath help stop early stage MS? Fascinating possibility – A drug developed to fight leukemia appears to stop multiple sclerosis in its early stages and restore lost function to patients, British researchers said on Wednesday…more

Forest Labs growing green – Forest Laboratories Inc posted higher-than-expected quarterly profit on Tuesday, fueled by stronger sales of its drugs for Alzheimer’s disease and depression and lower research spending…more

Biologics and safety concerns: really not a big surprise here – Approximately one in four biologics approved since 1995 in the US and Europe have had at least one safety-related regulatory action issued for them 10 years after their approval, including about 11 percent receiving a Black Box warning, according to a study in the Journal of the American Medical Association…more

Take a Chill, Pill: are oral cancer drugs all they’re cracked up to be?

B-I has some encouraging potential early results for novel cancer drugs.

The WSJ talks about healthcare, IT, and the future. Interesting stuff.

Reblog this post [with Zemanta]

Read Full Post »

Looks, on the surface, like a good match of products and market presence – Celgene buys Pharmion. And, in other important oncology news, Nexavar (from Bayer) gets expedited approval for liver cancer.

Also, Schering cleared to take over Organon – by divesting bird vaccines to Wyeth.

Read Full Post »